RecruitingPhase 2NCT07571746

A Study to Assess the Effect of Surovatamig in Adult Participants With Antibody-mediated Kidney Disease

A Phase 2, Open-label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of Surovatamig in Adults With Antibody-mediated Kidney Disease

Sponsor

AstraZeneca

Enrollment

43 participants

Start Date

Mar 28, 2026

Study Type

INTERVENTIONAL

Conditions

Primary Membranous Nephropathy

Summary

The purpose of this study is to assess the safety, tolerability, pharmacokinetic, and efficacy of surovatamig administered by subcutaneous injection in adult participants with primary membranous nephropathy.

Eligibility

Min Age: 18 YearsMax Age: 75 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called Surovatamig for people with primary membranous nephropathy. The study is currently recruiting participants at 22 locations. People eligible for this study include aged 18 Years to 75 Years.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGSurovatamig

Participants will receive Surovatamig subcutaneously

Locations(22)

Research Site

Los Angeles, California, United States

Research Site

Iowa City, Iowa, United States

Research Site

Bethesda, Maryland, United States

Research Site

New York, New York, United States

Research Site

Houston, Texas, United States

Research Site

Houston, Texas, United States

Research Site

Ieper, Belgium

Research Site

Bordeaux, France

Research Site

Créteil, France

Research Site

Lyon, France

Research Site

Nantes, France

Research Site

Nîmes, France

Research Site

Düsseldorf, Germany

Research Site

Brescia, Italy

Research Site

Rozzano, Italy

Research Site

Torino, Italy

Research Site

Verona, Italy

Research Site

Lodz, Poland

Research Site

Barcelona, Spain

Research Site

Madrid, Spain

Research Site

London, United Kingdom

Research Site

Manchester, United Kingdom

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07571746

Related Trials

A Phase 2 Study of Budoprutug in Subjects With Primary Membranous Nephropathy

NCT0709684343 locations

Evaluation of Efficacy, Safety, and Tolerability of Povetacicept in Participants With Primary Membranous Nephropathy (pMN)

NCT07204275102 locations

A Study of SNP-ACTH (1-39) Gel in Patients With Primary Membranous Nephropathy

NCT0569661331 locations

A Study to Learn More About the Effects and Safety of Felzartamab Infusions in Adults With Primary Membranous Nephropathy (PMN)

NCT06962800103 locations

Study of ALXN1920 in Adult Participants With Primary Membranous Nephropathy (PMN)

NCT0715778740 locations